Research Papers: Immunology:

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells

PDF |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:28294-28308. https://doi.org/10.18632/oncotarget.25511

Metrics: PDF 568 views  |   HTML 795 views  |   ?  

Eva Hajek, Franziska Krebs, Rebekka Bent, Katharina Haas, Antje Bast, Ivo Steinmetz, Andrea Tuettenberg, Stephan Grabbe _ and Matthias Bros


Eva Hajek1, Franziska Krebs1, Rebekka Bent1, Katharina Haas1, Antje Bast2, Ivo Steinmetz2, Andrea Tuettenberg1, Stephan Grabbe1,* and Matthias Bros1,*

1Department of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany

2Friedrich Loeffler Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany

*These authors contributed eqully to this work

Correspondence to:

Stephan Grabbe, email: stephan.grabbe@unimedizin-mainz.de

Keywords: BRAFV600E inhibitor; MEK inhibitor; dendritic cell; IL-1beta; inflammasome; Immunology

Received: September 19, 2017     Accepted: May 13, 2018     Published: June 19, 2018


Melanoma is the most dangerous form of skin cancer with a growing incidence over the last decades. Fourty percent of all melanomas harbor a mutation in the signaling adaptor BRAF (V600E) that results in ERK hyperactivity as an oncogenic driver. In these cases, treatment with the BRAFV600E inhibitors Vemurafenib (VEM) or Dabrafenib (DAB) coapplied with the MEK1/2 inhibitors Cobimetinib (COB) or Trametinib (TRA) can result in long-term suppression of tumor growth. Besides direct suppression of ERK activity, these inhibitors have been reported to also modulate tumor immune responses, and exert pro-inflammatory side effects such as fever and rash in some patients. Here we asked for potential effects of BRAFV600E inhibitors on dendritic cells (DC) which are essential for the induction of adaptive anti-tumor responses. Both splenic and bone marrow-derived (BM) mouse dendritic cells (DC) up-regulated costimulator expression (CD80, CD86) in response to DAB but not VEM treatment. Moreover, DAB and to lesser extent VEM enhanced IL-1β (interleukin 1 beta) release by splenic DC, and by LPS-stimulated BMDC. We demonstrate that DAB and VEM activated the NLRC4/Caspase-1 inflammasome. At high concentration, DAB also induced inflammasome activation independent of Caspase-1. TRA and COB elevated MHCII expression on BMDC, and modulated the LPS-induced cytokine pattern. Immunomodulatory activity of DAB and VEM was also observed in human monocyte-derived DC, and DAB induced IL-1β in human primary DC. Altogether, our study shows that BRAFV600E inhibitors upregulate IL-1β release by mouse and human DC which may affect the DC-mediated course of anti-tumor immune responses.

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells | Hajek | Oncotarget


Until a few years ago, no effective drug was available for treatment of metastatic melanoma. This situation changed with the introduction of immunotherapeutics and targeted therapies for melanoma treatment, including antibody-based immunotherapeutic approaches that block the inhibitory CTLA4-CD80/CD86 and PD1-PD-L1 signaling axes apparent in all types of tumor progression (reviewed in [1].

In addition, mutagenome analysis identified a common point mutation within the BRAF (v-Raf murine sarcoma viral oncogene homolog B) protein (BRAFV600E) apparent in >40% of all melanoma cases [2]. BRAF serves as an adaptor kinase in the ERK (extracellular signal-regulated kinases) pathway that transmits stimulatory signals of receptor binding growth factors [3]. Activation of ERK results in cell cyle progression, and thereby cell proliferation [4]. In case of BRAFV600E, autoinhibiton of BRAF is prevented which results in hyperactivation of ERK. Hence, BRAFV600E constitutes an oncogenic driver.

To terminate BRAFV600E-mediated constitutive ERK signaling in tumor cells, several small molecule inhibitors have been developed. Of these, Vemurafenib (VEM) and Dabrafenib (DAB) have been clinically approved for treatment of unresectable stage III and of stage IV melanoma [5]. However, tumor resistance towards BRAFV600E inhibitor therapy was observed in about half of all patients after 6–8 months of treatment. By now, a number of resistance mechanisms that result in reactivation of ERK have been identified, including the induction of BRAF isoforms [6], amplification of the BRAF gene locus [7], and activating mutations of other signaling molecules within the ERK pathway [8]. To prevent reactivation of ERK signaling, small molecule inhibitors that target signaling adaptors downstream of BRAF have been introduced [9]. Indeed, treatment of patients with VEM plus the MEK inhibitor cobimetinib (COB) [10], and of DAB coapplied with the MEK inhibitor trametinib (TRA) [11] significantly prolonged progression-free and overall survival of melanoma patients as compared with the according BRAFV600E inhibitor monotherapy.

These kinds of combination therapies were reported not only to inhibit the ERK pathway in tumor cells, but to also exert immuno-relevant effects that may significantly contribute to their clinical efficacy [12]. In this regard, treatment of melanoma cells in vitro with BRAFV600E inhibitors resulted in elevated presentation of melanoma-associated antigens, irrespective of the melanoma BRAF mutation state [13]. In addition, treatment of melanoma with VEM was reported to inhibit BRAFV600E-induced IL-1 (interleukin 1) production by melanoma cells and thereby to diminish IL-1 dependent production of protolerogenic prostaglandins and PD-L1/2 in the tumor micro-environment [14]. Likewise, cotreatment of melanoma patients with VEM and COB was shown to reduce VEGFR expression at the tumor site [15]. Furthermore, effector T cells were reported to be stimulated via so-called paradoxical activation of ERK signaling by BRAFV600E inhibitors [16]. In agreement, tumor specimens of patients under treatment with BRAFV600E plus MEK inhibitors showed increased infiltration with cytotoxic T cells [15]. Altogether, these findings indicate that BRAFV600E inhibitors may exert anti-tumor activity due to direct tumor-associated effects, but also via off target effects on immune cells.

Dendritic cells (DC) are crucial for the induction of adaptive anti-tumor T cell responses [17]. Here we asked for potential off target effects of VEM and DAB, and of the according MEK inhibitors COB and TRA on the immuno-phenotype of DC when applied at clinically relevant doses. We show that DAB alone partially activated splenic and bone marrow-derived (BM) mouse dendritic cells (DCs) as reflected by elevated costimulator expression (CD80, CD86) and strongly increased IL-1β levels. DAB enhanced both IL-1β mRNA expression and inflammasome activation via NLRC4. At high dose, DAB acted in a Caspase-1 independent manner via Caspase-8 to elevate IL-1β. TRA alone stimulated MHCII expression, and had no detrimental effect on DAB-dependent IL-1β induction. In contrast to DAB, VEM alone yielded no DC activation, but enhanced IL-1β as well, although at much lower level than observed for DAB. VEM enhanced IL-1β mRNA expression as well, and strictly required NLRC4/Caspase-1 inflammasome activation to induce IL-1β expression in BMDC. Both BRAFV600E inhibitors also elevated IL-1β secretion by splenic DC.


DAB enhances expression of costimulators by DC, in synergy with TRA, and TRA alone elevates MHCII expression

Our study aimed to elucidate potential off-target effects of clinically relevant BRAFV600E inhibitors on immune cells. Due to the dual role of DC for the maintenance of peripheral tolerance and the induction of primary immune responses we used mouse bone marrow-derived DC (BMDC) for subsequent experiments.

In melanoma therapy, BRAFV600E inhibitors are commonly coapplied with an assigned MEK1/2 inhibitor to efficiently block ERK signaling in tumor cells and thus to provide development of resistance mechanisms. In this regard, DAB is administered in combination with Trametinib (TRA). Viability analysis showed that when applied alone both DAB and TRA (Supplementary Figure 1A) yielded no major cytotoxic effects on CD11c+ BMDC at concentrations below 10 μM at unstimulated state (upper panel) and when coapplied with LPS (lower panel). Coapplication of DAB in combination with TRA resulted in a more pronounced decrease in viability. In subsequent experiments non-toxic concentrations were used as indicated. Similar effects were obtained with VEM and COB, although these substances were somewhat more toxic when applied at higher doses (Supplementary Figure 1B).

DAB enhanced expression of CD86 as well as of CD80 (Figure 1A) and of MHCII (Figure 1B) at high (CD86: 5 μM) and intermediate (CD80, MHCII: 2.5 μM) doses. TRA had no effect on the expression of costimulators, but enhanced MHCII expression. More strikingly, DAB (1 μM) and TRA (0.01 μM) when coapplied at low concentrations upregulated expression of CD80 and CD86 at maximal extent. Coapplication of DAB and TRA stimulated MHC-II expression at similar extent as observed for application of either agent alone. DAB applied at non-toxic concentrations (Supplementary Figure 2A) also activated splenic antigen presenting cell (APC) populations as reflected by elevated CD86 expression (Supplementary Figure 2B). Stimulation of BMDC with LPS as an internal control resulted in upregulation of all surface activation markers monitored which was not strongly affected by additional application of DAB and TRA (not shown).

DAB elevates costimulator expression by BMDC, and TRA enhances MHCII expression.

Figure 1: DAB elevates costimulator expression by BMDC, and TRA enhances MHCII expression. DAB and Trametinib (TRA) were applied alone or in combination at the concentrations indicated to unstimulated BMDC. DMSO (1‰) served as a solvent control (Ctrl). After 24 h, expression of (A) CD80, CD86, and (B) of MHCII by CD11c+ BMDC was assessed by flow cytometry. (A, B) Data show the MFI of the respective surface marker on pre-gated CD11c+ BMDC, normalized to the expression in Ctrl, arbitrarily set to 100% in each experiment. Data represent the mean ± SEM of 3–4 independent experiments each. (B, right panel), Histogram of MHCII expression by CD11c+ BMDC after differential treatment is representative of 3 independent experiments each. (A, B) Statistical differences: *versus control (Ctrl). *p < 0.05, **p < 0.01, ***p < 0.001.

Altogether, these results indicate that DAB partially activates BMDC, enhanced by concurrent MEK1/2 inhibition.

DAB strongly upregulates IL-1β production by unstimulated and LPS-stimulated DC, but diminishes other proinflammatory cytokines

DAB had no overall stimulatory effect on cytokine production by unstimulated BMDC, but dose-dependently induced IL-1β, which was further enhanced in response to cotreatment with DAB and TRA at highest concentration (Supplementary Figure 3).

In addition, the LPS-induced expression pattern of proinflammatory cytokines (IL-1β, TNF-α, IL-12, IL-23) and of anti-inflammatory IL-10 was altered in response to treatment with DAB and TRA as depicted in Figure 2. Again, DAB strongly upregulated IL-1β secretion in a dose-dependent manner by ~100-fold as compared with the control. TRA alone exerted no major effect on IL-1β. However, TNF-α production was inhibited by DAB in combination with TRA in a dose-dependent manner. DAB also dose-dependently inhibited IL-12 and IL-23 production which was further diminished when TRA was coapplied. In contrast, DAB moderately elevated IL-10 levels at higher doses (2.5 μM, 5 μM). TRA attenuated IL-10 production when applied alone, and counteracted the moderate stimulatory effect of DAB on IL-10 when coapplied.

DAB strongly enhances IL-1&#x03B2; generation by stimulated BMDC, but diminishes production of other proinflammatory cytokines.

Figure 2: DAB strongly enhances IL-1β generation by stimulated BMDC, but diminishes production of other proinflammatory cytokines. BMDC were stimulated with LPS (1 μg/ml). Aliquots were treated in addition with DAB and TRA either alone or in combination at the concentrations indicated. DMSO (1‰) served as a solvent control (Ctrl). After 24 h, supernatants were harvested for cytokine detection by CBA. Data represent mean ± SEM of 3–4 independent experiments each. Statistical differences: *versus control (Ctrl). *p < 0.05, **p < 0.01, ***p < 0.001.

These observations indicate that DAB besides its stimulatory effects on the BMDC surface marker phenotype also strongly altered the cytokine pattern of DC, with potent induction of IL-1β and suppression of IL-12, IL-23 and TNF-α production.

VEM exerts no stimulatory effect on BMDC, but COB elevates MHCII expression

Next we asked whether the profound effects of DAB and TRA on the immuno-phenotype of DC were agent-specific. To this end, we also included the clinically applied BRAFV600E inhibitor VEM and the coadministerd MEK1/2 inhibitor COB in our analysis. In contrast to DAB, VEM had no effect on the expression of costimulatory surface receptors CD80 and CD86 of BMDC (Figure 3A) as well as the surface level of MHCII (Figure 3B). In agreement, VEM at non-toxic concentrations (Supplementary Figure 2A) yielded no effect on CD86 expression by splenic APC (Supplementary Figure 2B). The MEK1/2 inhibitor COB which is coapplied with VEM in therapy had no effect on the expression of costimulatory surface receptors CD80 and CD86 (Figure 3A), but at high concentration (1 μM) elevated their MHCII expression. However, coapplication of VEM (2.5 μM) and COB (0.025 μM COB) at intermediate doses resulted in enhanced surface levels of both costimulators (CD80, CD86), while MHCII expression remained unaffected. VEM and COB had no effect on the expression of MHCII and costimulators of LPS-stimulated BMDC (not shown).

The MEK inhibitor Cobimetinib enhances expression of costimulators (CD80, CD86) by BMDC when coapplied with VEM, and elevates MHCII expression when applied alone.

Figure 3: The MEK inhibitor Cobimetinib enhances expression of costimulators (CD80, CD86) by BMDC when coapplied with VEM, and elevates MHCII expression when applied alone. VEM and Cobimetinib (COB) were applied alone or in combination at the concentrations indicated to unstimulated BMDC. DMSO (1‰) served as a solvent control (Ctrl). After 24 h, expression of (A) CD80, CD86, and (B) of MHCII by CD11c+ BMDC was assassed by flow cytometry. (A and B, right panel) Data show the MFI of the according surface marker on pre-gated CD11c+ BMDC, normalized to the expression in Ctrl, arbitrarily set to 100% in each experiment. Data represent the mean ± SEM of 3–4 independent experiments each. (B, right panel) Histogram of MHCII expression by CD11c+ BMDC after differential treatment is representative of 3 independent experiments each. (A, B) Statistical differences: *versus control (Ctrl). *p < 0.05, **p < 0.01, ***p < 0.001.

These results suggest that DAB-induced enhancement of costimulator expression by BMDC is a substance-specific, rather than a drug class-specific off target effect of BRAFV600E inhibitors.

VEM enhances IL-1β release by LPS-stimulated DC, completely blocked by coapplied COB

Similar to DAB, VEM enhanced IL-1β secretion by LPS-stimulated BMDC in a dose-dependent manner (Figure 4). However, on an equimolar base DAB induced at least 10-fold more IL-1β than VEM. Furthermore, while TRA did not interfere with DAB-dependent IL-1β induction, COB completely abrogated VEM-dependent IL-1β upregulation. With regard to other cytokines, TNF-α and IL-23 were not strongly affected by VEM and COB, in contrast to the inhibitory effects of DAB and TRA on both cytokines. Similarly, while DAB inhibited IL-12, VEM at high concentration (5 μM) enhanced IL-12 levels, largely abrogated upon coapplication of COB (0.05 μM). Similar to DAB, VEM and COB attenuated IL-10 levels, further diminished by coappliction of VEM and COB in a dose-dependent manner.

VEM elevates IL-1&#x03B2; production of LPS-stimulated BMDC, abrogated by cotreatment with COB.

Figure 4: VEM elevates IL-1β production of LPS-stimulated BMDC, abrogated by cotreatment with COB. BMDC were stimulated with LPS (1 μg/ml). Aliquots were treated in addition with VEM and COB either alone or in combination at the concentrations indicated. DMSO (1‰) served as a solvent control (Ctrl). After 24 h, supernatants were harvested for cytokine detection by CBA. Data represent mean ± SEM of 3–4 independent experiments each. Statistical differences: *versus control (Ctrl). *p < 0.05, **p < 0.01, ***p < 0.001.

These results indicate that BRAFV600E inhibitors as a common off target effect elevate IL-1β production, but otherwise qualitatively differ in their effects on other components of the DC immunophenotype.

VEM and DAB enhance IL-1β expression on mRNA level and via inflammasome activation

As outlined above, of all cytokines monitored, only IL-1β secretion was commonly upregulated by both BRAFV600E inhibitors in LPS-stimulated BMDC, albeit at much higher extent by DAB than by VEM. In addition, DAB (Supplementary Figure 3) but not VEM (not shown) also enhanced IL-1β secretion in unstimulated BMDC. Similar findings were observed for splenic CD11c+ DC as assessed by intracellular staining of IL-1β (Supplementary Figure 4, upper panel). However, in this DC population also VEM induced IL-1β producing cells, at similar extent as observed for DAB. CD68+ macrophages in spleen showed no major upregulation of the frequency of IL-1β producing cells in response to DAB and VEM (Supplementary Figure 4, lower panel). In contrast, VEM and DAB had no IL-1β promoting effect on splenic CD19+ B cells (not shown).

Due to the immunological importance of IL-1β, we asked by which mechanisms the two BRAFV600E inhibitors enhanced IL-1β secretion in myeloid APC. In unstimulated BMDC, DAB induced IL-1β cytokine secretion after 24 h of treatment (Figure 5A, left panel) which corroborated our previous finding (Supplementary Figure 3). Elevated IL-1β secretion was paralleled by transiently enhanced IL-1β mRNA levels 6 h after DAB application (Figure 5B, left panel). Translation of IL-1β mRNA results in pre IL-1β which requires cleavage to yield mature IL-1β protein. Cleavage of pre IL-1β is mediated by an activated inflammasome complex. Inflammasomes consist of multi-protein complexes which are triggered by various stimuli to activate Caspase-1 which in turn cleaves pre IL-1β. We observed that DAB enhanced inflammasome activation in BMDC as reflected by an elevated frequency of Caspase-1+ BMDC monitored 6 h after the onset of treatment (Figure 5C, left panel). On the contrary, VEM alone had no effect on IL-1β mRNA levels (Figure 5B, left panel), and a very moderate effect on Caspase-1 activation only (Figure 5C, left panel).

VEM and DAB enhance IL-1&#x03B2; expression on transcriptional level and by inflammasome activation.

Figure 5: VEM and DAB enhance IL-1β expression on transcriptional level and by inflammasome activation. BMDC were treated with VEM and DAB (each 5 μM), and aliquots were cotreated with LPS (1 μg/ml). DMSO (1‰) served as a solvent control (Ctrl). At the indicated time points aliquots were harvested, and (A) IL-1β contents were assayed by CBA, and (B) IL-1β mRNA levels were assassed by QPCR, and were normalized to expression in the corresponding control. (C) After 6 h of coincubation, BMDC were incubated with cell permeant FLICA reagent specifically cleaved to a fluorphoric product by active Caspase-1. BMDCs treated with ATP (5 mM) served as a positive control. Frequencies of Caspase-1 positive cells were assessed by flow cytometry, and values were normalized to the corresponding control. (A–C) Data represent mean ± SEM of 3–4 independent experiments each. Statistical differences: (A–C) *versus corresponding control (Ctrl), (A) +versus control at 1 h. *,+p < 0.05, **,++p < 0.01.

In case of LPS-stimulated BMDC, DAB cotreatment strongly elevated IL-1β cytokine contents at all time points assessed, whereas coapplication of VEM resulted in higher IL-1β protein levels only at 24 h after onset of treatment (Figure 5A, right panel). While DAB exerted no effect on IL-1β mRNA levels in LPS-stimulated BMDC, VEM enhanced IL-1β mRNA contents at 24 h after coapplication (Figure 5B, left panel). DAB-dependently upregulated IL-1β cytokine contents were associated with increased Caspase-1 activation, while VEM evoked only a moderate effect in this regard (Figure 5C, right panel).

Altogether, VEM and DAB elevated IL-1β secretion in a differential manner: While DAB acted on transcriptional level only in case of unstimulated BMDC, and stimulated inflammasome activity in BMDC at either state of activation, VEM elevated IL-1β mRNA levels in LPS-stimulated BMDC only and yielded moderate inflammasome activation.

DAB and VEM act via NLRC4/caspases-1, and DAB also via caspase-8 to elevate IL-1β release

To elucidate which molecular components of the inflammasome were activated by DAB and VEM, BMDC were pretreated with respective inhibitors prior to application of intermediate doses of either BRAFV600E inhibitor (each 2.5 μM). DAB-mediated induction of IL-1β was strongly attenuated in response to inhibition of Caspase-1 with Ac-YVAD, and upon application of the dual NLRP3/NLRC4 inhibitor genipin, but only moderately affected when using specific NLRP3 (CC950) and dual NLRP3/AIM2 (ethanol) inhibitors (Figure 6A, upper left panel). As previously observed, cotreatment of BMDC with DAB and LPS resulted in much stronger upregulation of IL-1β as compared with application of DAB or LPS alone. Under these conditions, only inhibition of Caspase-1 and NLRC4 markedly attenuated IL-1β levels (Figure 6A, upper right panel). VEM-induced IL-1β upregulation was abolished upon inhibition of Caspase-1, and in the presence of genipin (Figure 6A, lower panel). Altogether, these findings suggest that both BRAFV600E inhibitors act via canonical NLRC4/Caspase-1 inflammasome activation to elevate IL-β secretion.

VEM and DAB activate NLRC4/Caspase-1 to induce IL-1&#x03B2; release, but DAB at higher concentration also acts in a Caspase-1/11-independent manner.

Figure 6: VEM and DAB activate NLRC4/Caspase-1 to induce IL-1β release, but DAB at higher concentration also acts in a Caspase-1/11-independent manner. (A) BMDC were treated with pharmacological inhibitors of Caspase-1 (Ac-YVAD [50 μM]), NLRP3 (CC950 [100 nM]), NLRP3/AIM2 (ethanol [0.5‰]), and NLRP3/NLRC4 (genipin [50 μM]) at non-toxic concentrations. After 45 min, VEM and DAB (each 2.5 μM) were applied. In case of DAB treatment, aliquots were cotreated with LPS (1 μg/ml). DMSO (1‰) served as a solvent control (-). (B) BMDC (wild type [WT], Casp1/11--) were treated with VEM and DAB (each 1 μM and 5 μM), and aliquots were cotreated with LPS (1 μg/ml). DMSO (1‰) served as a solvent control (Ctrl). (A, B) On the next day, IL-1β contents of BMDC supernatants were assayed by CBA. Data represent mean ± SEM of 3 (B) or 4 (A) independent experiments each. Statistical differences: *versus corresponding control (Ctrl), +versus WT at same conditon, $versus BRAFV600E inhibitor-treated sample w/o additional inflammasome inhibitor. *,+p < 0.05, **,++,$$p < 0.01, ***,+++,$$$p < 0.001.

To confirm the importance of Caspase-1 for BRAFV600E inhibitor induced IL-1β release, we employed Caspase-1/11-/- BMDC. Of note, DAB alone at high concentration (5 μM) induced IL-1β in BMDC irrespective of Caspase-1/11 expression (Figure 6B, left panel). When coapplied with LPS, DAB at lower dose (1 μM) induced IL-1β release also in Caspase-1/11-/- BMDC, but at markedly lower levels as compared with the corresponding wild type (WT) control (Figure 6B, right panel). However, when DAB was coapplied with LPS at higher dose (5 μM) IL-1β levels were comparable in supernatants of both BMDC populations. In contrast, VEM induced IL-1β only when coapplied with LPS. These results suggested that while VEM critically depends on Caspase-1 activation, DAB at higher concentration also acted in a Caspase-1 independent manner. Pharmacological inhibiton of Caspase-8 strongly inhibited DAB-induced IL-1β secretion (DAB alone: by 56%, DAB+LPS: by 88%; not shown).

Altogether, these results indicate that DAB and VEM commonly act via NLRC4/Caspase-1 inflammasome activation to promote maturation of pre IL-1β. However, DAB but not VEM at high dose is able to activate Caspase-8 for IL-1ß maturation as an alternative mechanism.

BRAFV600E inhibitors modulate the immuno-phenotype of human monocyte-derived (MO)DC, and DAB induces IL-1β in human primary DC

Finally, we asked for effects of BRAFV600E inhibitors on human DC. For this, we differentiated MODC derived from progenitors of healthy volunteers. In contrast to our findings in mouse, VEM but not DAB yielded enhanced costimulator expression (Supplementary Figure 5A). However, in accordance with BMDC, DAB applied for 6 h upregulated IL-1β mRNA expression (Supplementary Figure 5B), and both BRAFV600E inhibitors moderately upregulated Caspase-1 activity when applied for 6 h (Supplementary Figure 5C). Unfortunately, we detected no elevated IL-1β in supernatants of BRAFi-treated MODC (data not shown). However, when testing effects of BRAFi on primary human DC isolated from PBMC we observed an increase in IL-1ß levels in most samples after treatment with DAB (Supplementary Figure 5D), but not for VEM (not shown). This finding is in agreement with the observation of marked induction of IL-1ß mRNA and Caspase-1 by DAB in unstimulated MODC. Altogether, these findings show that BRAFV600E inhibitors exert yet undescribed immunomodulatory effects on APC in a DC population- and species-dependent manner.


The BRAFV600E inhibitors VEM and DAB are one treatment of choice for BRAFV600E metastatic melanoma [18]. Due to frequent occurence of tumor resistance towards treatment both BRAFV600E inhibitors are coapplied with according MEK inhibitors [10, 11]. These combinations are more effective to abolish ERK hyperactivity in melanoma and exert sustained activity. Tumor cell death is induced by ERK inhibition, but immuno-relevant mechanisms like enhanced antigen presentation by tumor cells as induced by BRAFV600E inhibitors [13], and paradoxical ERK activation in effector T cells as induced by MEK inhibitors [16] may also contribute to therapeutic effects.

In light of the role of DC for the induction and polarization of adaptive anti-tumor responses [17] here we asked for potential off target effects of BRAFV600E inhibitors and for the immuno-modulatory role of coapplied MEK inhibitors at therapeutically relevant doses.

We demonstrate that DAB alone partially activates mouse splenic APC populations and BMDC as reflected by elevated expression of MHCII and costimulators (CD80, CD86), while VEM yielded no such effect. ERK signaling was reported to maintain DC in an immature state [19]. In agreement, both MEK inhibitors (COB, TRA) induced upregulation of MHCII by BMDC, but had no effect on costimulator expression. However, coapplication of VEM and COB yielded stimulatory effects on CD80 and CD86 expression. Similarly, combined treatment with DAB and TRA at the lowest concentrations tested induced profound elevation of both costimulators. Somewhat different to our findings in mouse, VEM alone upregulated costimulator expression by human MODC while DAB exerted no stimulatory effect. In previous studies VEM [20] and DAB [21] were reported to yield no immuno-modulatory effects on human MODC. Interestingly, Tel and coworkers [22] showed that VEM, but not DAB interfered with R848-induced upregulation of surface activation markers and cytokines by human primary DC. However, the inhibitiory effect of VEM on DC activation was largely prevented when applying VEM to total PBMC.

In agreement with the partially stimulatory activity of TRA on mouse BMDC, Vella and coworkers demonstrated a stimulatory effect of this MEK inhibitor on MODC as well, while the opposite was reported by Ott et al. [20] which may be attributed to methodological differences in DC differentiation.

Unexpected DC stimulatory properties have been reported for other anti-tumor drugs as well. In this regard, we have previously demonstrated that topotecan [23] and the heat shock protein 90 inhibitor geldanamycin [24] stimulated MODC which was associated with NF-kB activation. Further studies are required to identify the molecular targets of BRAFV600E inhibitors in DC which contribute to cellular stimulation. When treated with LPS as a very potent DC stimulator, BRAFV600E inhibitors and MEK inhibitors exerted no additional modulatory effect on the expression of DC activation markers (data not shown). Similar observations were obtained in our aforementioned studies on the DC-stimulatory effects of chemotherapeutics. Our finding of DAB-mediated upregulation of MHCII and costimulators by DC suggests that DAB as an off-target effect stimulates NF-kB activation via yet unknown molecular targets.

In our study, the BRAF and MEK inhibitors tested altered the cytokine pattern of LPS-stimulated BMDC. On an equimolar base DAB and TRA mediated stronger inhibitory effects than VEM and COB in case of TNF-α, IL-12 and IL-23. In contrast to these inhibitory effects, IL-1β was upregulated by both BRAFV600E inhibitors, with DAB being much more potent on an equimolar base than VEM. Besides, while COB abolished VEM-induced IL-1β upregulation, TRA exerted no inhibitory effect on DAB-dependent IL-1β upregulation. Both BRAFV600E inhibitors also enhanced IL-1β secretion by splenic DC and to minor extent by macrophages, but not by B cells.

In several studies chemotherapeutics including doxorubicin, daunorubicin [25] and vincristine [26] were demonstrated to elevate IL-1β release by DC and macrophages by triggering the NLRP3 inflammasome, and subsequent Caspase-1 activation. These drugs act on primed myeloid APC characterized by elevated IL-1β transcription and pre IL-1β production. We show that even DAB alone elevated IL-1β secretion by unstimulated BMDC via transcriptional upregulation of IL-1β mRNA, and inflammasome activation, which was also observed in case of human MODC. In contrast, VEM elevated IL-1β levels only in LPS-stimulated BMDC primarily by enhancing IL-1β mRNA expression at later time points. However, in human MODC also VEM exerted moderate Caspase-1 activation. Altogether, these results suggest that BRAFV600E inhibitors act at both levels of IL-1β regulation in a species- and DC population-dependent manner.

In clinical practice, drug side effects to BRAFV600E inhibitors differ markedly between patients: whereas some suffer from pronounced rash towards VEM or fever attacks in response to DAB, other patients show no such side effects. Thus, there appear to exist genetic polymorphisms that control these immunomodulatory effects of BRAFV600E inhibitors in humans. This assumption is confirmed by our finding that a fraction of human primary DC sampels did not responded to DAB treatment with regard to elevated IL-1β production.

As mentioned above, several chemotherapeutics were demonstrated to activate the NLRP3 inflammasome shown to sense various pathogen-derived and endogenous danger signals [25]. However, we show that the BRAFV600E inhibitors tested elevated IL-1β in a NLRP3-independent manner, but via NLRC4. So far, flagellin has been identified as the major inducer of the NLRC4 inflammasome [27]. We also show that VEM requires Caspase-1 to cleave pre IL-1β, while DAB at higher concentrations induced IL-1β independent of Caspase-1. Pharmacological inhibition of Caspase-8 partially inhibited DAB-mediated IL-1β induction. Besides activation of the NLRP3/Caspase-1 axis, more recently doxorubicin and staurosporine were also found to promote IL-1β maturation in a Caspase-1 independent manner via a FADD/Caspase-8 complex termed riptoptosome [28]. Further studies are necessary to clarify which proteins are targeted by DAB to facilitate IL-1β release.

IL-1 has early been attributed anti-apoptotic and stimulatory effects on DC [29]. In agreement, IL-1β was demonstrated to play an essential role in the induction of adaptive anti-tumor immune responses [30]. In chemically induced colon cancer models mice with a defective inflammasome showed stronger tumor induction and progression than WT mice suggesting a protective role of the inflammasome [31]. In contrast, in other tumor models including melanoma, inflammasome activity supported tumor growth [32]. In line, many human tumors including advanced melanomas are characterized by high level IL-1β production due to both elevated pre IL-1β expression and enhanced Caspase-1 activity [33]. Several studies have revealed different tumor-promoting effects of IL-1β. In an autocrine manner, tumor-derived IL-1β stimulated melanoma cell proliferation [34]. In addition, tumor-derived IL-1β was shown to be essential for conversion of fibroblasts into cancer-associated fibroblasts [35], which expressed the immuno-suppressive receptors PD-L1 and PD-L2 [14]. IL-1β generated by tumor cells and by tumor-associated macrophages in an autocrine manner induced CCL2 secretion which in turn attracted macrophages [30]. Furthermore, transcriptional reprogramming of tumor-infiltrating myeloid cells was mediated in part by IL-1β induced NF-kB activation [36]. Besides, tumor neoangiogenesis was shown to be promoted by IL-1β induced COX-2 [37]. Above, IL-1 was shown to stimulate the expression of endothelial adhesion molecules that may favor interaction with spreading tumor cells, and hence metastasis [38].

While inflammasome activity in tumor cells enabled the aforementioned tumor-promoting effects, immune cells that produce IL-1β exert stronger tumor-suppressive function [39]. In agreement, anti-tumor chemotherapeutics are most efficient when they induce immunogenic tumor cell death, accompanied by IL-1β induction in immune cells [32]. The latter is initiated by the release of endogenous danger signals like ATP derived from mitochondria of necrotic tumor cells [39] which stimulates the NLRP3 inflammasome of myeloid APC by binding to purinergic receptors [40]. In an autocrine manner, IL-1β stimulates APC via activation of NF-kB [41]. Moreover, APC-derived IL-1β promotes T cell-driven anti-tumor responses by favouring Tc1 [42] and Th1/Th17 polarization [43], and by activating γδ T cells [44]. In agreement with these beneficial effects of IL-1β generated by APC, mice upon blockade of IL-1 signaling [45] do not respond to chemotherapy with immunogenic cell death inducers like anthracyclines.

In metastatic melanoma the BRAFV600E mutation was reported to elevate production of IL-1α and IL-1β, abrogated after treatment with VEM [14]. We show here that BRAFV600E inhibitors promote IL-1β secretion in DC via the NLRC4 inflammasome, and in case of DAB also in a Caspase-1 independent manner. Therefore, BRAFV600E inhibitors in a cell type- or microenvironment-specific manner inhibit (tumor) and promote (APC) IL-1β secretion. On the contrary, currently used chemotherapeutics activate the NLRP3 inflammasome at differential extent in a more unspecific manner and thereby may cause side effects such as cardiotoxicity (anthracyclines) [25], intestinal mucositis (5-fluoruracil) [46], or pulmonary fibrosis (bleomycin) [47]. To prevent these IL-1β related cytotoxic effects as well as adverse effects of IL-1β within the tumor microenvironment (see above), administration of IL-1β inhibitors has been suggested [32]. However, systemic IL-1β inhibition may compromise anti-tumor immune responses that depend on immunogenic cell death, and immune responses against infections [48].

Further studies are required to elucidate the cell type specificity of BRAFV600E inhibitor induced IL-1β secretion. In case of APC-restricted inflammasome activation these agents may be well suited to exploit the beneficial effects of APC-associated IL-1β for tumor therapy.



VEM, DAB, COB and TRA were obtained from Selleck Chemicals (Houston, TX, USA). Ac-YVAD-cmk, CC950, and Genipin were purchased from Tocris (Bristol, UK), and ethanol was obtained from Roth (Karlsruhe, Germany).


Female C57BL/6J mice were obtained from Janiver Labs (Saint Berthevin Cedex, France) and were maintained in the Translational Animal Research Center of the University Medical Center Mainz under pathogen-free conditions on a standard diet. The recommendations of the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health were followed.

Spleen cells were isolated from spleens of 6–12 week old mice, using a 40 μM cell strainer (Greiner Bio-One, Frickenhausen, Germany) to generate a single cell suspension in culture medium (IMDM with 5% Fetal Bovine Serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin [all from Sigma-Aldrich, Deisenhofen, Germany], and 50 μM ß-mercaptoethanol [Roth, Karlsruhe, Germany]).

Bone marrow (BM)-derived DC (BMDC) were differentiated from progenitors of 6–12 week old mice as described [49]. To this end, BM cells (2 × 105/ml) were seeded either in 12 well plates (1 ml) or in 10 cm bacterial dishes (10 ml) (both from Greiner Bio-One) in culture medium (see above) supplemented with 10 ng/ml recombinant murine GM-CSF (R&D Systems, Wiesbaden, Germany). Media was replenished on days 3 and 6 of culture. Aliquots of non-adherent and loosely adherent immature BMDC were harvested on days 7 or 8 of culture for subsequent experiments. Where indicated, BRAFV600E and MEK1/2 inhibitors were coapplied. In all other cases of BMDC treatment with different agents, inflammasome inhibitors were applied first, and BRAFV600E inhibitors, and LPS (1 μg/ml, Merck Millipore, Billerica, MA, USA) were administered sequentially at temporal distances of 1 h. DMSO (1‰) served as solvent control. One day later samples were analysed.

Surface marker expression

BMDC cultures (12 well plates) and freshly isolated spleen cells (5 × 105/ml) seeded in 12 well plates (1 ml) were treated with inhibitors and LPS. One day later, cells were harvested and washed in staining buffer (PBS/2% FCS). Cells were incubated with rat anti-mouse CD16/CD32 antibody (clone 2.4G2) for 15 min at room temperature. Afterwards, spleen cells were incubated with (APC)-conjugated anti-CD11c (clone N418), PE-conjugated anti-CD68 (clone FA-11), FITC-conjugated anti-CD19 (clone 1D3) and PE-Cy7-labeled anti-CD86 (GL1) antibodies. BMDC were incubated with APC-conjugated anti-CD11c, eFluor450-conjugated anti-MHC class II (clone M5/114.15.2), FITC-conjugated anti-CD80 (16-10A1), and PE-Cy7-labeled anti-CD86 antibodies. All antibodies were purchased from Biolegend or affymetrix/eBioscience (both San Diego, CA, USA). Samples were analyzed using a BD FACS CANTO II flow cytometer (BD Biosciences, San Jose, CA, USA). Data were analyzed using FlowJo software (FLOWJO, Ashland, OR, USA). The gating strategy is depicted in Supplementary Figure 6.

Caspase-1 activity

To detect activated Caspase-1 in BMDC, the Flica 660 Caspase-1 Assay Kit (ImmunoChemicals, Bloomington, USA) was used following the manufacturer’s instructions. For this, BMDC (12 well plates) were treated with the indicated agents for 6 h prior to analysis, and assayed by flow cytometry (see above)

Cytokine detection

Cytokine contents of BMDC supernatants were quantified by Cytometric bead array (BD Bioscience). For this, BMDC (10 cm dishes) were harvested and were reseeded in cell-culture treated 24 well plates (106/ml). BMDC were differentially treated, and supernatants were collected on the next day and analyzed using the mouse CBA flex sets following the manufacturer´s instructions.

Real-time PCR analysis

Total RNA was isolated from BMDC using the RNeasy MiniPlus kit (Qiagen, Hilden, Germany), and reverse-transcribed by employing the iScript kit (Bio-Rad, Munich, Germany) as recommended by the manufacturer. Primer pairs used to detect expression of IL-1β and the house-keeping gene ubiquitin C were obtained from eurofins MWG Synthesis (Ebersberg, Germany). Primer sequences and data analysis have been described [49].

Statistical analysis

Data are presented as means ± SEM of the values. Data were analyzed for statistically significant differences by applying one-way ANOVA followed by Tukey´s test for post hoc analysis using SigmaPlot 12.3 (Systat Software, San Jose, CA).


AIM2: absent in melanoma 2; APC: antigen presenting cell; BMDC: bone marrow-derived dendritic cell; BRAF: v-Raf murine sarcoma viral oncogene homolog B; CD: cluster of differentiation; COB, Cobimetinib; COX-2: Cyclooxygenase-2; DAB: Dabrafenib; DC: dendritic cell; ERK: extracellular signal regulated kinase; FADD: Fas (tumor necrosis factor receptor superfamily 6)-associated via death; IL: interleukin; LPS: lipopolysaccharid; MEK, mitogen-activated protein kinase/ERK kinase; MODC: monocyte-derived DC; NF-kB: nuclear factor - kappa-light-chain-enhancer of activated B-cells; NLRC4: ‘nucleotide-binding domain, leucine-rich repeat’ family, CARD domain containing 4; NLRP3: ‘nucleotide-binding domain, leucine-rich repeat’ family, pyrin domain containing 3; PD-L1: programmed death-ligand 1; PD-L2: Programmed death-ligand 2; Tc1: cytotoxic T cell type 1; Th1: T helper cell type 1; Th17: Th type 17; TNF-α: tumor necrosis factor alpha; TRA: Trametinib; VEM: Vemurafenib.

Author contributions

M.B., S.G., and A.T. designed the study. E.H., F.K., R.B., and K.H. performed the experiments. E.H., A.B., I.S., and A.T. analysed the data. M.B. and S.G. prepared the manuscript with help from coauthors.


The authors thank E. Montermann and I. Tubbe (Dept. of Dermatology, University Medical Center Mainz) for technical assistance.


The authors have no conflicts of interest to disclose.


This study was supported by intramural funding of the FZI (Forschungszentrum Immunolotherapy) of the University Medical Center Mainz.


1. Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol. 2017; 43:604–611. https://doi.org/10.1016/j.ejso.2016.07.145.

2. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, Mason G, Magee J, Angel C, Dobrovic A, McArthur GA. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol. 2007; 127:900–5.

3. Campbell PM. Oncogenic Ras pushes (and pulls) cell cycle progression through ERK activation. Methods Mol Biol. 2014; 1170:155–63.

4. Wellbrock C, Arozarena I. The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Front Cell Dev Biol. 2016; 4:33.

5. Luke JJ, Hodi FS. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist. 2013; 18:717–25.

6. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480:387–90.

7. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012; 3:724.

8. Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? Eur J Cancer. 2016; 62:76–85.

9. Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene. 2013; 32:2373–9.

10. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371:1867–76.

11. Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res. 2014; 20:2035–43.

12. Manzano JL, Layos L, Bugés C, de Los Llanos Gil M, Vila L, Martínez-Balibrea E, Martínez-Cardús A. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016; 4:237.

13. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010; 70:5213–9.

14. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012; 18:5329–40.

15. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19:1225–31.

16. Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, Russell V, Gordon RA, Vyas S, Yuan J, Gupta A, Wigginton JM, Rosen N, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res. 2014; 2:70–9.

17. Hansen M, Andersen MH. The role of dendritic cells in cancer. Semin Immunopathol. 2017; 39:307–16.

18. Simeone E, Grimaldi AM, Festino L, Vanella V, Palla M, Ascierto PA. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. BioDrugs. 2017; 31:51–61.

19. Kikuchi K, Yanagawa Y, Iwabuchi K, Onoé K. Differential role of mitogen-activated protein kinases in CD40-mediated IL-12 production by immature and mature dendritic cells. Immunol Lett. 2003; 89:149–54.

20. Ott PA, Henry T, Baranda SJ, Frleta D, Manches O, Bogunovic D, Bhardwaj N. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother. 2013; 62:811–22.

21. Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, Louahed J, Chen W, Woods K, Cebon JS. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res. 2014; 2:351–60.

22. Tel J, Koornstra R, de Haas N, van Deutekom V, Westdorp H, Boudewijns S, van Erp N, Di Blasio S, Gerritsen W, Figdor CG, de Vries IJ, Hato SV. Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. J Transl Med. 2016; 14:88.

23. Trojandt S, Knies D, Pektor S, Ritz S, Mailänder V, Grabbe S, Reske-Kunz AB, Bros M. The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells. Cancer Immunol Immunother. 2013; 62:1315–26.

24. Trojandt S, Reske-Kunz AB, Bros M. Geldanamycin-mediated inhibition of heat shock protein 90 partially activates dendritic cells, but interferes with their full maturation, accompanied by impaired upregulation of RelB. J Exp Clin Cancer Res. 2014; 33:16.

25. Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther. 2011; 11:1008–16.

26. Wong J, Tran LT, Magun EA, Magun BE, Wood LJ. Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine. Cancer Biol Ther. 2014; 15:1395–403.

27. Lage SL, Longo C, Branco LM, da Costa TB, Buzzo CL, Bortoluci KR. Emerging Concepts about NAIP/NLRC4 Inflammasomes. Front Immunol. 2014; 5:309.

28. Antonopoulos C, El Sanadi C, Kaiser WJ, Mocarski ES, Dubyak GR. Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1β via caspase-8 in dendritic cells. J Immunol. 2013; 191:4789–803.

29. Grabbe S, Bruvers S, Granstein RD. Effects of immunomodulatory cytokines on the presentation of tumor-associated antigens by epidermal Langerhans cells. J Invest Dermatol. 1992; 99:66S–68S.

30. Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep. 2016; 6:36107.

31. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C, Ting JP. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010; 207:1045–56.

32. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol. 2012; 13:343–51.

33. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, Dinarello CA, Fujita M. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem. 2010; 285:6477–88.

34. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, Grimm EA. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res. 2011; 9:1537–50.

35. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia. 2013; 15:409–20.

36. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008; 14:408–19.

37. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M, Ono M. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest. 2005; 115:2979–91.

38. Scherbarth S, Orr FW. Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: effects of interleukin-1alpha on metastasis and the location of B16F1 melanoma cell arrest. Cancer Res. 1997; 57:4105–10.

39. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA, Leemans JC, Sutterwala FS. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A. 2009; 106:20388–93.

40. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15:1170–8.

41. Yoshimura A, Mori H, Ohishi M, Aki D, Hanada T. Negative regulation of cytokine signaling influences inflammation. Curr Opin Immunol. 2003; 15:704–8.

42. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011; 334:1573–7.

43. Hutton HL, Ooi JD, Holdsworth SR, Kitching AR. The NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology (Carlton). 2016; 21:736–44.

44. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011; 208:491–503.

45. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 2011; 71:4809–20.

46. Wu Z, Han X, Qin S, Zheng Q, Wang Z, Xiang D, Zhang J, Lu H, Wu M, Zhu S, Yu Y, Wang Y, Han W. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-Fluorouracil in a mouse mucositis model. Biomed Pharmacother. 2011; 65:339–44.

47. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VF, Lagente V, Ryffel B, Couillin I. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest. 2007; 117:3786–99.

48. Netea MG, van de Veerdonk FL, van der Meer JW, Dinarello CA, Joosten LA. Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol. 2015; 33:49–77.

49. Bros M, Jährling F, Renzing A, Wiechmann N, Dang NA, Sutter A, Ross R, Knop J, Sudowe S, Reske-Kunz AB. A newly established murine immature dendritic cell line can be differentiated into a mature state, but exerts tolerogenic function upon maturation in the presence of glucocorticoid. Blood. 2007; 109:3820–9.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25511